Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information

v3.8.0.1
Note 11 - Segment Information
 3 Months Ended
Sep. 30, 2017
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
11.
Segment Information:
 
The Company's management evaluates segment operating performance based on operating income before certain charges t
o cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses.
 
The following is finan
cial information relating to the Company's reportable segments (in thousands):
 
   
Quarter Ended
  
   
September 30,
  
   
2017
    
2016
  
Net sales:
                
Biotechnology
   $
95,076
     $
86,787
  
Protein
Platforms
    
24,640
      
19,573
  
Diagnostics
    
24,986
      
24,233
  
In
tersegment
    
(89
)
    
(12
)
Consolidated net sales
   $
144,613
     $
130,581
  
O
perating income:
                
Biotechnology
   $
44,603
     $
42,480
  
Protein Platforms
    
3,056
      
209
  
Diagnostics
    
5,829
      
6,303
  
Segment operating income
    
53,488
      
48,992
  
Costs recognized on sale of acquired inventory
    
(318
)
    
(1,344
)
Amortization of acquisition related intangible assets
    
(11,379
)
    
(10,188
)
Acquisition related expenses
    
(9,533
)
    
(3,532
)
Stock
based compensation
    
(3,795
)
    
(3,190
)
Corporate general, selling, and administrative
expenses
    
(2,432
)
    
(1,582
)
Consolidated operating income
   $
26,031
     $
29,156